1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 to 75 Sponsor: Other Protocol IDs: CGC05MK1002, NCT00188149
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 50 Sponsor: Other Protocol IDs: BARTS-TE3, EU-20608, ISRCTN08648791, NCT00324298
|
|
4.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 15 to 70 Sponsor: Other Protocol IDs: CDR0000531125, EORTC-20051, GELA-H10, IIL-EORTC-20051, EUDRACT-2005-002765-37, EU-20657, NCT00433433
|
|
5.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD18, NCT00515554
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: HD16, NCT00736320
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: IIL-HD0801, EudracT Number 2008-002684-14, NCT00784537
|
|
10.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 16 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: ASI-HDIII 0109, NCT00816959
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 75 Sponsor: Other Protocol IDs: CHNT-RAPID, RAPID, ISRCTN99811594, EU-20931, NCT00943423
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FM-HD09-01, EudraCT N 2009-009431-30, NCT00992030
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD17, NCT01356680
|
|
15.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 16 to 60 Sponsor: Other Protocol IDs: Casasnovas PHRC N 2010, NCT01358747
|
|
16.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018
|
|
17.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 to 60 Sponsor: Other Protocol IDs: EORTC-20101-23101, 2011-005473-22, NCT01652261
|
|
18.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 to 60 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GAINED, NCT01659099
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 03-Z 16/KSOPKR-6, NCT01264952
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: MRC-TE23, EU-205107, ISRCTN53643604, EUDRACT-2004-000405-22, NCT00301782
|
|
22.
|
Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: ISRA2432_CTIL, NCT00392314
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 40 Sponsor: Other Protocol IDs: CRCA-CCTC-ACCELERATED-BEP, CCTC-ACCELERATED-BEP, EUDRACT-2004-000847-79, EU-20713, NCT00453232
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2007-0144, NCT00654732
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07-388, NCT00722865
|